Sunil Bodanapu
About Sunil Bodanapu
Sunil Bodanapu has 7 years in corporate governance. Holds Designated Partner and Director roles. Currently with 3 companies, including Entelei Proto Llp and Nushift Technologies Private Limited. Formerly with 1 company, such as Bharat Growth Capital Private Limited. Engaged in General Business, Technology and more. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Entelei Proto Llp
AAP-7799
|
Designated Partner | 28 Jun 2019 | 2019 | Active |
Nushift Technologies Private Limited
U72900TG2019PTC135353
|
Director | 11 Sep 2019 | 2019 | Active |
|
Innate Health Care (Ihc) Private Limited
U85200TG2019PTC129880
|
Director | 21 Jan 2019 | 2019 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
|
Bharat Growth Capital Private Limited
U67190TG2021PTC150546
|
Director | 13 Apr 2021 | 2021 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sunil Bodanapu
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sunil Bodanapu
Sunil Bodanapu has 7 years in corporate governance. Holds Designated Partner and Director roles. Currently with 3 companies, including Entelei Proto Llp and Nushift Technologies Private Limited. Formerly with 1 company, such as Bharat Growth Capital Private Limited. Engaged in General Business, Technology and more. Contributes to corporate operations.
Sunil Bodanapu is associated with 3 companies as Designated Partner and Director.
Sunil Bodanapu has expertise in General Business, Technology and other sectors.
Sunil Bodanapu has 7 years in corporate governance.